Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects

Psychopharmacology

Volumn 218, Issue 4, 2011, Pages 649-665

  Griffiths, Roland R ^a   Johnson, Matthew W ^a   Richards, William A ^b   Richards, Brian D ^b   McCann, Una ^a   Jesse, Robert ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c Council on Spiritual Practices ^*  (United States)

Author keywords

Dose effects; Entheogen; Fear; Hallucinogen; Humans; Mystical experience; Positive psychology; Psilocybin; Psychedelic; Religion; Spiritual

Indexed keywords

PLACEBO; PSILOCYBINE;

ABSENCE OF SIDE EFFECTS; ADDICTION RESEARCH CENTER INVENTORY; ADULT; ALTRUISM; ANXIETY; APZ; ARTICLE; ATTENTION; ATTITUDE; ATTITUDE TO LIFE; BEHAVIOR CHANGE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEAR; FEMALE; FOLLOW UP; HALLUCINOGEN RATING SCALE; HAPPINESS; HUMAN; HUMAN EXPERIMENT; LIFE SATISFACTION; MALE; MOOD CHANGE; MYSTICISM; MYSTICISM SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; OUTCOME ASSESSMENT; PERCEPTION; PERSISTING EFFECTS QUESTIONNAIRE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELIGION; SELF CONCEPT; SOCIAL BEHAVIOR; STATE OF CONSCIOUSNESS QUESTIONNAIRE; SYSTOLIC BLOOD PRESSURE; VOLUNTEER;

ADULT; AFFECT; ATTITUDE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; PSILOCYBINE; QUESTIONNAIRES; SPIRITUALITY; TIME FACTORS;

EID: 82955203431     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2358-5     Document Type: Article

References (41)

1. HD Abraham AM Aldridge P Gogia 1996 The psychopharmacology of hallucinogens Neuropsychopharmacology 14 285 298 8924196 10.1016/0893-133X(95) 00136-2 1:CAS:528:DyaK28Xitl2ntLw%3D (Pubitemid 26120555)
2. Blewett DB., Chwelos N (1959) Handbook for the therapeutic use of lysergic acid diethylamide-25: individual and group procedures. Available at http://www.erowid.org/psychoactives/guides/handbook-lsd25.shtml#11. Accessed January 4, 2011
3. A Dittrich 1998 The standardized psychometric assessment of altered states of consciousness (ASCs) in humans Pharmacopsychiatry 31 Suppl 2 80 84 9754838 10.1055/s-2007-979351 (Pubitemid 28396276)
4. R Doblin 1991 Pahnke's Good Friday experiment: a long-term follow-up and methodological critique J Transpers Psychol 23 1 28
5. RA Glennon M Titeler D McKenney 1984 Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents Life Sci 35 2505 2511 6513725 10.1016/0024-3205(84)90436-3 1:CAS:528:DyaL2MXlsF2luw%3D%3D (Pubitemid 15212191)
6. RR Griffiths CS Grob 2010 Hallucinogens as medicine Scientific American 303 77 79 10.1038/scientificamerican1210-76
7. RR Griffiths WA Richards U McCann R Jesse 2006 Psilocybin can occasion mystical experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology (Berl) 187 268 283 10.1007/s00213-006-0457-5 1:CAS:528:DC%2BD28XntVCqurY%3D (Pubitemid 44088380)
8. RR Griffiths WA Richards MW Johnson U McCann R Jesse 2008 Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later J Psychopharmacol 22 6 621 632 18593735 10.1177/0269881108094300 1:CAS:528:DC%2BD1MXjtVyhsLc%3D
9. CS Grob AL Danforth GS Chopra M Hagerty CR McKay AL Halberstadt GR Greer 2011 Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer Arch Gen Psychiatry 68 1 71 78 20819978 10.1001/archgenpsychiatry.2010.116 1:CAS:528:DC%2BC3MXhtVKrtr8%3D
10. G Guzmán 2008 Hallucinogenic mushrooms in Mexico: an overview Econ Bot 62 404 412 10.1007/s12231-008-9033-8
11. CA Haertzen 1966 Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI) Psychol Rep 18 163 194 5908477 10.2466/pr0.1966.18.1.163 1:STN:280:DyaF287gs1Oisg%3D%3D
12. JH Halpern HG Pope 1999 Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 53 247 256 10080051 10.1016/S0376-8716(98)00129-X 1:CAS:528:DyaK1MXivVOqtQ%3D%3D (Pubitemid 29027995)
13. F Hasler U Grimberg MA Benz T Huber FX Vollenweider 2004 Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study Psychopharmacology (Berl) 172 145 156 10.1007/s00213-003-1640-6 1:CAS:528:DC%2BD2cXhsFyktb8%3D (Pubitemid 38388763)
14. LE Hollister 1961 Clinical, biochemical and psychologic effects of psilocybin Arch Int Pharmacodyn Ther 130 42 52 13715376 1:CAS:528: DyaF3MXms1Cksw%3D%3D
15. RW Hood Jr RJ Morris 1983 Toward a theory of death transcendence J Sci Stud Rel 22 4 353 365 10.2307/1385773
16. RW Hood Jr N Ghorbani PJ Watson AF Ghramaleki MN Bing HK Davison RJ Morris WP Williamson 2001 Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran J Sci Stud Rel 40 691 705 10.1111/0021-8294.00085
17. Hood RW Jr, Hill PC, Spilka B (2009) The psychology of religion: an empirical approach, 4th edn. Guilford, New York
18. H Isbell 1959 Comparison of the reactions induced by psilocybin and LSD-25 in man Psychopharmacologia 1 29 38 14405870 10.1007/BF00408109 1:CAS:528:DyaF3cXisVyisw%3D%3D
19. Jasinski DR (1977) Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction. Springer, New York, pp 197-258
20. MW Johnson WA Richards RR Griffiths 2008 Human hallucinogen research: guidelines for safety J Psychopharmacol 22 6 603 620 18593734 10.1177/0269881108093587 1:CAS:528:DC%2BD1MXjtVyhsLk%3D
21. E Kast 1967 Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide Psychiatr Q 41 646 657 4169685 10.1007/BF01575629 1:STN:280:DyaF1c7itFKntQ%3D%3D
22. T Leary GH Litwin R Metzner 1963 Reactions to psilocybin administered in a supportive environment J Nerv Ment Dis 137 561 573 14087676 10.1097/00005053-196312000-00007 1:STN:280:DyaF2c%2FksFeguw%3D%3D
23. S Malitz H Esecover B Wilkens PH Hoch 1960 Some observations on psilocybin, a new hallucinogen, in volunteer subjects Compr Psychiatry 1 8 17 14420328 10.1016/S0010-440X(60)80045-4 1:STN:280:DyaF3c7ntlSisQ%3D%3D
24. WR Martin JW Sloan JD Sapira DR Jasinski 1971 Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man Clin Pharmacol Ther 12 245 258 5554941 1:CAS:528:DyaE3MXhtl2gtLw%3D
25. Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano
26. R Metzner G Litwin G Weil 1965 The relation of expectation and mood to psilocybin reactions: a questionnaire study Psychedelic Rev 5 3 39
27. Miller WR, C'de Baca J (2001) Quantum change: when epiphanies and sudden insights transform ordinary lives. Guilford, New York
28. DE Nichols 2004 Hallucinogens Pharmacol Ther 101 131 181 14761703 10.1016/j.pharmthera.2003.11.002 1:CAS:528:DC%2BD2cXptFCmsg%3D%3D (Pubitemid 38167565)
29. Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society
30. WN Pahnke 1969 Psychedelic drugs and mystical experience Int Psychiatry Clin 5 149 162 4892137 1:STN:280:DyaF1M3ht1OnsQ%3D%3D
31. WA Richards S Grof LE Goodman AA Kurland 1972 LSD-assisted psychotherapy and the human encounter with death J Transpers Psychol 4 2 121 150
32. WA Richards JC Rhead FB DiLeo R Yensen AA Kurland 1977 The peak experience variable in DPT-assisted psychotherapy with cancer patients J Psychedelic Drugs 9 1 10 (Pubitemid 8106580)
33. M Rinkel CR Atwell A Dimascio J Brown 1960 Experimental psychiatry. V. Psilocybine, a new psychotogenic drug N Engl J Med 262 295 297 14437505 10.1056/NEJM196002112620606 1:CAS:528:DyaF3cXjvF2jsA%3D%3D
34. DE Rosenberg H Isbell EJ Miner CR Logan 1964 The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide Psychopharmacologia 5 217 227 14138757 10.1007/BF00413244 1:CAS:528: DyaF2cXkt1OrtL4%3D
35. Stamets P (1996) Psilocybin mushrooms of the world: an identification guide. Ten Speed, Berkeley
36. Stolaroff MJ (1997) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies, Sarasota
37. RJ Strassman CR Qualls EH Uhlenhuth R Kellner 1994 Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale Arch Gen Psychiatry 51 98 108 8297217 1:CAS:528:DyaK2cXis1Sgs7c%3D (Pubitemid 24054311)
38. IS Turek RA Soskin AA Kurland 1974 Methylenedioxyamphetamine (MDA) subjective effects J Psychedelic Drugs 6 7 14
39. VandeCreek L (1999) The death transcendence scale. In: Hill PC, Hood RW Jr (eds) Measures of religiosity. Religious Education Press, Birmingham, pp 442-445
40. Wasson RG (1980) The wondrous mushroom: mycolatry in Mesoamerica. McGraw-Hill, New York
41. AB Wolbach Jr EJ Miner H Isbell 1962 Comparison of psilocin with psilocybin, mescaline and LSD-25 Psychopharmacologia 3 219 223 14007905 10.1007/BF00412109 1:CAS:528:DyaF2cXjsVWrtw%3D%3D